medwireNews: Combining metformin with a sulfonylurea (SU) produces poorer non-glycemic outcomes than combining it with different second-line brokers, present outcomes from the worldwide DISCOVER program.
All combos resulted in related glycemic management in the long run, however Kamlesh Khunti (College of Leicester, UK) and co-investigators stress that “you will need to think about different elements within the administration of [type 2 diabetes].”
They discovered that use of metformin plus an SU resulted in much less weight reduction, extra hypoglycemia, and poorer high quality of life, in contrast with all different combos.
“Regardless of this, combos of metformin and an SU have been prescribed to a big proportion of individuals, echoing outcomes from an observational examine carried out within the UK and Germany,” the researchers write in Diabetes Weight problems and Metabolism.
They attribute this to the low availability and excessive price of different glucose-lowering medicines within the lower-income international locations included within the DISCOVER examine program.
“For instance, combos of metformin and an SU have been prescribed to 94% of sufferers from the African area, whereas in Europe such combos have been solely prescribed to 30% of sufferers,” they are saying.
The DISCOVER program covers 38 international locations, grouped into World Well being Group areas. This evaluation included 7613 individuals, aged a median of 57 years, who have been taking a metformin mixture for sort 2 diabetes. Of those individuals, 40.9% have been utilizing an SU, 48.3% a dipeptidyl peptidase (DPP)-4 inhibitor, 8.3% a sodium-glucose cotransporter (SGLT)2 inhibitor, and a couple of.4% a glucagon-like peptide (GLP)-1 receptor agonist.
Though individuals initially achieved considerably bigger reductions in glycated hemoglobin with metformin combos apart from SUs, this distinction disappeared after 12 months, at which level solely use of a DPP-4 inhibitor was related to considerably higher glycemic management relative to make use of of an SU.
However individuals taking an SU with metformin had the smallest weight reduction in any respect measured timepoints as much as and together with 36 months, whereas metformin plus a GLP-1 receptor agonist persistently delivered the most important reductions, of roughly 5 kg at 36 months, in contrast with 1 kg for the SU mixture.
Hypoglycemic occasions have been commonest in individuals taking an SU with metformin, at round 12% by 36 months of therapy, in contrast with about 3–6% for the opposite metformin combos.
Lastly, individuals taking an SU with metformin had destructive adjustments in psychological high quality of life in any respect timepoints, and in bodily high quality of life at most, though the researchers word that these adjustments from baseline have been “modest.” In contrast, individuals taking different second-line brokers had enhancements in any respect or most timepoints.
“These actual world information recommend that metformin together with a DPP-4 inhibitor, an SGLT-2 inhibitor, or a GLP-1 receptor agonist maintain vital advantages at second line compared with metformin and an SU, including further proof to assist steerage which recommends SU mixture therapies provided that price or availability is a matter,” conclude the researchers.
medwireNews is an impartial medical information service offered by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, a part of the Springer Nature Group